RECRUITING

Effects of an Antioxidant Supplement on Blood Vessel Health

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide, and the non-Hispanic Black (NHB) population is disproportionately affected. Our research has previously demonstrated that oxidative stress may contribute to reduced vascular function in otherwise healthy NHB adults, potentially predisposing them to the development of hypertension and CVD. This study is designed to examine whether the mitochondria are an important source of oxidative stress-induced vascular dysfunction in healthy NHB adults.

Official Title

Role of Mitochondria-derived Oxidative Stress on Microvascular Endothelial Function in Healthy Non-Hispanic Black and White Adults

Quick Facts

Study Start:2024-07-01
Study Completion:2030-03-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06424756

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 75 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Self-identify as either non-Hispanic Black or non-Hispanic White.
  2. * Men and women 18-75 years old.
  3. * Non-hypertensive (systolic blood pressure \[SBP\]\<130 and diastolic blood pressure \[DBP\] \<85 mmHg).
  4. * Have low density lipoprotein cholesterol \<150mg/dl.
  5. * Have HbA1C \<6.0%.
  1. * Rash, skin disease, or disorders of pigmentation (e.g., psoriasis, eczema, vitiligo, or other skin inflammatory skin disorders)
  2. * Known skin allergies to latex or adhesives
  3. * Smoking and/or use of nicotine-containing products within the past year
  4. * Use of illegal/recreational drugs
  5. * Generalized kidney disease
  6. * Taking chloramphenicol, cholestyramine, medication for seizures, methotrexate, nitrofurantoin, tetracycline, barbiturates, steroids, phenobarbital/phenytoin, orlistat or pyrimethamine
  7. * Any current medications which could conceivably alter the cardiovascular control or responses
  8. * Diagnosed or suspected metabolic or cardiovascular disease
  9. * Current pregnancy or breastfeeding
  10. * History of skin or other cancers
  11. * Diagnosed or suspected diabetes (HbA1c ≥6.0)
  12. * Anybody with narcolepsy or who has been diagnosed with any condition that impairs body temperature regulation.

Contacts and Locations

Study Contact

S. Tony Wolf
CONTACT
706-542-4378
stwolf@uga.edu
Melissa Gorejena
CONTACT
mgorejena@uga.edu

Study Locations (Sites)

Ramsey Student Center, University of Georgia
Athens, Georgia, 30602
United States

Collaborators and Investigators

Sponsor: University of Georgia

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-07-01
Study Completion Date2030-03-31

Study Record Updates

Study Start Date2024-07-01
Study Completion Date2030-03-31

Terms related to this study

Keywords Provided by Researchers

  • Vascular dysfunction
  • Cardiovascular disease
  • Hypertension
  • Nitric oxide
  • Endothelial function

Additional Relevant MeSH Terms

  • Healthy